BCCA Protocol Summary for Treatment of Cutaneous T-cell Lymphoma (Sézary syndrome) with Extracorporeal Photopheresis

**Protocol Code:** ULYMFECP

**Tumour Group:** Lymphoma

**Contact Physician:** Dr. Laurie Sehn

**ELIGIBILITY:**
- Special: Only patients with advanced, progressive, refractory cutaneous T-cell lymphoma (erythroderma or stages T2/3 with circulating Sézary cells) who have failed at least two prior systemic chemotherapy agents, not including retinoids, and have failed or are unable to tolerate Bexarotene should be considered for ECP. This means that they have either failed to respond to or have relapsed after these treatments.
- Histology: mycosis fungoides or Sézary syndrome
- Adequate immune system with near normal WBC (excluding Sézary cells)
- Normal/near normal CD8 count
- An “Undesignated Indications Request Form” must be approved.

**EXCLUSIONS:**
- Large tumour burden
  - Lymphocytes greater than 25,000
  - Bulky adenopathy greater than or equal to 7 cm
  - Overt visceral organ involvement
  - Multiple tumours
- Large cell transformation
- Significant immunosuppression
- Hypersensitivity to Psoralen
- HIV positive
- Considered on an individual basis: hepatitis B and C
- Insufficient venous access
- Prior prolonged combination chemotherapy or prolonged multiple courses of single agent chemotherapy

**TESTS:**
- Baseline (required before first treatment): CBC & diff, platelets, bilirubin, AST, ALT, smear for Sézary cells, CD4 and CD8 counts, LDH, PTT, INR.
- Baseline (required, but results do not have to be available to proceed with first treatment; results must be checked before proceeding with further treatment): HBsAg, HBcoreAb
- Before each treatment: CBC and diff, platelets

**PREMEDICATIONS:**
- None

**SUPPORTIVE MEDICATIONS:**
If HBsAg or HBcoreAb positive, start lamivUDine 100 mg/day PO for the duration of ECP therapy and for six months afterwards.
TREATMENT:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extracorporeal Photopheresis (ECP)</td>
<td>0.017 times the final buffy coat volume in millilitres (varies from 3-6 mL/treatment; 6 to 12 mg on two consecutive days every 4 weeks)</td>
<td>Infused into the product bag immediately before phototherapy</td>
</tr>
<tr>
<td>8-methoxypsoralen (Uvadex)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Reassess all sites of disease after 6 months. Initial treatment is 6 months. Consider a further 6 months of treatment for responders

DOSE MODIFICATIONS:

None

PRECAUTIONS:

1. **Photosensitivity**: Minimise exposure to sunlight and artificial UV light during treatment. It is recommended that patients wear sunscreen greater than or equal to SPF 15 and sunglasses for 24 hours after treatment.

2. **Hepatitis B Reactivation**: All lymphoma patients should be tested for both HBsAg and HBcoreAb. If either test is positive, such patients should be treated with lamivudine during chemotherapy and for six months afterwards. Such patients should also be monitored with frequent liver function tests and hepatitis B virus DNA at least every two months. If the hepatitis B virus DNA level rises during this monitoring, management should be reviewed with an appropriate specialist with experience managing hepatitis and consideration given to halting chemotherapy.

Call Dr. Laurie Sehn or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date activated: 01 Apr 2006

Date revised: 1 Jun 2014 (Hepatitis reactivation management clarified)

References:


